RUZZA, Chiara
 Distribuzione geografica
Continente #
NA - Nord America 5.668
AS - Asia 3.181
EU - Europa 1.804
SA - Sud America 539
AF - Africa 76
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.273
Nazione #
US - Stati Uniti d'America 5.548
SG - Singapore 1.226
CN - Cina 706
IT - Italia 518
VN - Vietnam 433
BR - Brasile 404
DE - Germania 236
HK - Hong Kong 229
PL - Polonia 192
GB - Regno Unito 164
FI - Finlandia 141
UA - Ucraina 135
BD - Bangladesh 126
FR - Francia 124
TR - Turchia 103
JP - Giappone 83
RU - Federazione Russa 80
IN - India 73
CA - Canada 69
AR - Argentina 56
ID - Indonesia 53
SE - Svezia 51
MX - Messico 32
NL - Olanda 30
ZA - Sudafrica 29
IQ - Iraq 25
PK - Pakistan 25
EC - Ecuador 20
ES - Italia 20
IE - Irlanda 19
BE - Belgio 18
AT - Austria 15
UZ - Uzbekistan 15
VE - Venezuela 15
CZ - Repubblica Ceca 14
CO - Colombia 13
LT - Lituania 13
AE - Emirati Arabi Uniti 11
KE - Kenya 10
TN - Tunisia 10
PH - Filippine 9
SA - Arabia Saudita 9
PE - Perù 7
PY - Paraguay 7
UY - Uruguay 7
CH - Svizzera 6
KR - Corea 6
MY - Malesia 6
NP - Nepal 6
AZ - Azerbaigian 5
CL - Cile 5
DZ - Algeria 5
KZ - Kazakistan 5
MA - Marocco 5
AL - Albania 4
BG - Bulgaria 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
EG - Egitto 4
IL - Israele 4
JM - Giamaica 4
JO - Giordania 4
RO - Romania 4
BO - Bolivia 3
KW - Kuwait 3
NG - Nigeria 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
AU - Australia 2
BB - Barbados 2
CR - Costa Rica 2
GY - Guiana 2
IR - Iran 2
KG - Kirghizistan 2
LK - Sri Lanka 2
LV - Lettonia 2
NI - Nicaragua 2
OM - Oman 2
PA - Panama 2
PS - Palestinian Territory 2
TH - Thailandia 2
ZW - Zimbabwe 2
BJ - Benin 1
CI - Costa d'Avorio 1
DM - Dominica 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
LU - Lussemburgo 1
LY - Libia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
MN - Mongolia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
QA - Qatar 1
Totale 11.269
Città #
Ashburn 901
Singapore 759
Fairfield 498
San Jose 438
Woodbridge 401
Santa Clara 268
Beijing 250
Houston 239
Seattle 218
Hong Kong 217
Cambridge 194
Warsaw 186
Ann Arbor 183
Wilmington 183
Chandler 161
Ferrara 161
Jacksonville 154
Ho Chi Minh City 148
New York 141
Los Angeles 128
Hanoi 92
Munich 87
Tokyo 76
Helsinki 71
Shanghai 68
Dallas 65
Lauterbourg 65
Milan 63
Princeton 57
Council Bluffs 56
Izmir 53
Bologna 46
Nanjing 44
São Paulo 40
Jakarta 38
London 38
Chicago 34
San Diego 33
Dearborn 31
Orem 31
Da Nang 28
Turku 28
Boardman 27
Atlanta 26
Frankfurt am Main 25
Toronto 23
Brooklyn 21
Buffalo 20
Mexico City 19
Montreal 19
Dublin 18
Brussels 17
Denver 17
Belo Horizonte 16
Chennai 16
Falkenstein 16
Johannesburg 16
Lappeenranta 16
Phoenix 16
Rio de Janeiro 16
Addison 15
Moscow 14
Nanchang 14
Stockholm 14
Tashkent 14
Guangzhou 13
Hefei 13
Shenyang 13
Tianjin 13
Assago 12
Brasília 12
Falls Church 12
Manchester 12
Norwalk 12
The Dalles 12
Haiphong 11
Mumbai 11
Padova 11
San Francisco 11
Washington 11
Biên Hòa 10
Lahore 10
Nairobi 10
Vienna 10
Bremen 9
Dhaka 9
Poplar 9
Rome 9
Baghdad 8
Changsha 8
Hải Dương 8
Nuremberg 8
Porto Alegre 8
Redwood City 8
Amsterdam 7
Ankara 7
Bari 7
Boston 7
Guayaquil 7
Hebei 7
Totale 7.732
Nome #
Pharmacological and neurobiological studies on Neuropeptide S and its receptor 271
Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor 253
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 248
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 247
Biased Agonism at Nociceptin/Orphanin FQ Receptors: A Structure Activity Study on N/OFQ(1-13)-NH2 242
Neuropeptide S reduces mouse aggressiveness in the resident/intruder test through selective activation of the neuropeptide S receptor 241
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. 235
Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic- versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands 228
Modulation of the NOP receptor signaling affects resilience to acute stress 227
Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt(1)]N/OFQ(1-13) 222
Pharmacological characterization of tachykinin tetrabranched derivatives 214
Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test 213
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 212
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 210
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors 209
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 207
In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant 205
Neuropeptide S receptor ligands: a patent review (2005-2016) 204
In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations 200
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 199
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 196
Structure-activity study at positions 3 and 4 of human neuropeptide S. 194
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 194
Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies 193
Tetrabranched Hetero-Conjugated Peptides as Bifunctional Agonists of the NOP and Mu Opioid Receptors 192
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). 189
Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands 184
In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1 178
Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist 176
NOP agonist action of cebranopadol counteracts its liability to promote physical dependence 168
Novel Mixed NOP/Opioid Receptor Peptide Agonists 163
Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys 163
Structure-Activity Relationship Studies on Oxazolo[3,4- a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent in Vivo Activity 161
Lack of Direct Effects of Neurotrophic Factors in an In Vitro Model of Neuroinflammation 154
NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine 151
Functional Selectivity Does Not Predict Antinociceptive/Locomotor Impairing Potencies of NOP Receptor Agonists 151
Dopamine D1 and D2 receptors mediate neuropeptide S-induced antinociception in the mouse formalin test 141
In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative 140
Effects of non-peptide nociceptin/orphanin FQ receptor ligands on methylphenidate-induced hyperactivity in mice: Implications for bipolar disorders 140
The concise guide to pharmacology 2021/22: G protein-coupled receptors 140
Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors 138
Detailed in vitro pharmacological characterization of the clinically viable nociceptin/orphanin FQ peptide receptor antagonist BTRX-246040 133
Biased versus Partial Agonism in the Search for Safer Opioid Analgesics 127
Highly differentiated T cells link systemic and vascular inflammation in a mouse model of recurrent psoriasis 126
NOP Ligands for the Treatment of Anxiety and Mood Disorders 125
Blockade of nociceptin/orphanin FQ signaling facilitates an active copying strategy due to acute and repeated stressful stimuli in mice 125
Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress 119
Activation of NOP receptor increases vulnerability to stress: role of glucocorticoids and CRF signaling 115
The NOP antagonist BTRX-246040 increases stress resilience in mice without affecting adult neurogenesis in the hippocampus 114
Preclinical effects of cannabidiol in an experimental model of migraine 112
Pharmacological characterization of naloxegol: In vitro and in vivo studies 112
null 110
The concise guide to pharmacology 2019/20: G protein-coupled receptors 110
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. 109
Activation of peripheral NOP receptors reduces periorbital mechanical allodynia evoked by CGRP in mice 108
Nociceptin/orphanin FQ receptor agonists increase aggressiveness in the mouse resident-intruder test 108
Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice 106
null 105
Identification of isoxazole-based TRPA1 inhibitors with analgesic effects in vivo 104
In vitro pharmacological evaluation of the novel NOP receptor partial agonist sunobinop 100
Racemic synthesis and solid phase peptide synthesis application of the chimeric valine/leucine derivative 2-amino-3,3,4-trimethyl-pentanoic acid 99
In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays 98
Sex differences in response to NLRP3 inflammasome blockage in a mouse migraine model: A genetic and pharmacological study 96
Synthesis, Biological Activity and Molecular Docking of Chimeric Peptides Targeting Opioid and NOP Receptors 95
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors 95
Effects of Stress Exposure to Pain Perception in Pre-Clinical Studies: Focus on the Nociceptin/Orphanin FQ-NOP Receptor System 95
In vitro pharmacological characterization of standard and new lysophosphatidic acid receptor antagonists using dynamic mass redistribution assay 92
null 87
Pharmacology, physiology and genetics of the neuropeptide s system 81
null 77
Nociceptin/OrphaninFQ Receptor Modulates the Maturation of Adult-Born Neurons in the Mouse Dentate Gyrus Under Physiological Conditions and in a Chronic Stress Model 74
Synthesis and Pharmacological Characterization of Nociceptin/Orphanin FQ Dimeric Ligands 68
Nociceptin/orphanin FQ receptor system blockade as an innovative strategy for increasing resilience to stress 67
The concise guide to pharmacology 2017/18: Overview 61
An Insight into Neuronal Processing of Ghrelin: Effects of a Bioactive Ghrelin Derivative on Proteolytic Pathways and Mitophagy 55
null 42
Totale 11.443
Categoria #
all - tutte 52.285
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 780
Totale 53.065


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021123 0 0 0 0 0 0 0 0 0 0 74 49
2021/2022524 33 35 28 39 37 38 27 41 24 52 35 135
2022/2023455 58 42 23 48 58 44 39 37 50 5 27 24
2023/2024427 32 47 25 14 26 78 22 39 4 21 14 105
2024/20251.682 43 43 153 73 191 177 16 73 293 169 238 213
2025/20265.401 562 274 407 619 806 348 663 331 504 548 339 0
Totale 11.443